An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 225-232

  Pravetoni, Marco ^a,b   Le Naour, M ^c   Harmon, T M ^a   Tucker, A M ^a   Portoghese, P S ^c   Pentel, P R ^a,b,c  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; BUPRENORPHINE; DRUG ANTIBODY; DRUGS USED IN THE TREATMENT OF ADDICTION; GLYCINE; HEMISUCCINATE; KEYHOLE LIMPET HEMOCYANIN; METHADONE; OXYCODONE; OXYCODONE CONJUGATE VACCINE; OXYMORPHONE; SUCCINIC ACID; TETRAGLYCINE; UNCLASSIFIED DRUG; VACCINE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HAPTEN CARRIER COMPLEX; HOT PLATE TEST; IMMUNOGENICITY; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; THERMAL STIMULATION;

ANALGESIA; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; BRAIN; CATTLE; CHICKENS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HOT TEMPERATURE; MALE; OXYCODONE; PAIN; PAIN MEASUREMENT; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; VACCINES, CONJUGATE;

EID: 84858661736     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189506     Document Type: Article

References (40)

1. Anton B and Leff P (2006) A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24:3232-3240.
2. Anton B, Salazar A, Flores A, Matus M, Marin R, Hernandez JA, and Leff P (2009) Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin 5:214-229.
3. Berkowitz B and Spector S (1972) Evidence for active immunity to morphine in mice. Science 178:1290-1292.
4. Berkowitz BA, Ceretta KV, and Spector S (1974) Influence of active and passive immunity on the disposition of dihydromorphine-H3. Life Sci 15:1017-1028.
5. Bieniarz C, Barnes G, Welch CJ, and Schlesinger CA (1988) inventors; Abbott Laboratories, assignee. Preparation of poly(amino acid)-based heterobifunctional coupling agents and conjugates containing them. European patent application 314127 A2 19890503. 1988 Oct 27.
6. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, and Schuster CR (1974) Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252:708-710.
7. Carroll FI, Blough BE, Pidaparthi RR, Abraham P, Gong PK, Deng L, Huang X, Gunnell M, Lay JO Jr, Peterson EC, et al. (2011) Synthesis of mercapto-(+)- methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem 54:5221-5228.
8. Chan S, Edwards SR, Wyse BD, and Smith MT (2008) Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Clin Exp Pharmacol Physiol 35:295-302. (Pubitemid 351257877)
9. Chi KR (2011) Vaccines move forward against a range of addictions. Nat Med 17:146.
10. Compton WM and Volkow ND (2006) Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 81:103-107.
11. D'Aunno T and Vaughn TE (1992) Variations in methadone treatment practices. Results from a national study. JAMA 267:253-258.
12. Dodrill CL, Helmer DA, and Kosten TR (2011) Prescription pain medication dependence. Am J Psychiatry 168:466-471.
13. Fareed A, Vayalapalli S, Stout S, Casarella J, Drexler K, and Bailey SP (2011) Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis 30:27-38.
14. Findlay JW, Butz RF, and Jones EC (1981) Relationships between immunogen structure and antisera specificity in the narcotic alkaloid series. Clin Chem 27: 1524-1535. (Pubitemid 11013469)
15. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, et al. (1996) Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2:1129-1132. (Pubitemid 26338633)
16. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim RE, et al. (2011) Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89:392-399.
17. Hieda Y, Keyler DE, Vandevoort JT, Kane JK, Ross CA, Raphael DE, Niedbalas RS, and Pentel PR (1997) Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 283:1076-1081. (Pubitemid 28016479)
18. Hill JH, Wainer BH, Fitch FW, and Rothberg RM (1975) Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6- hemisuccinate bovine serum albumin. J Immunol 114:1363-1368.
19. Keyler DE, Hieda Y, St Peter J, and Pentel PR (1999) Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1:241-249.
20. Keyler DE, Roiko SA, Benlhabib E, LeSage MG, St Peter JV, Stewart S, Fuller S, Le CT, and Pentel PR (2005) Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 33:1056-1061. (Pubitemid 41002789)
21. Keyler DE, Roiko SA, Earley CA, Murtaugh MP, and Pentel PR (2008) Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 8:1589-1594.
22. Kubler-Kielb J, Liu TY, Mocca C, Majadly F, Robbins JB, and Schneerson R (2006) Additional conjugation methods and immunogenicity of Bacillus anthracis poly-γ-D-glutamic acid-protein conjugates. Infect Immun 74:4744-4749. (Pubitemid 44157262)
23. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, and Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461-479.
24. Lamont JV, McConnell RI, Fitzgerald SP, Benchikh EO, and Lowry AP (2003) inventors; Randox Laboratories Ltd., assignee. Preparation of haptens, immunogens and antibodies to oxycodone and its metabolites. European Patent Application 1323718 A2 20030702. 2003 Aug 21.
25. Lemberg K, Kontinen VK, Viljakka K, Kylänlahti I, Yli-Kauhaluoma J, and Kalso E (2006) Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg 102:1768-1774. (Pubitemid 43799854)
26. Leow KP, Smith MT, Watt JA, Williams BE, and Cramond T (1992) Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 14:479-484.
27. Lewis RJ, Johnson RD, and Hattrup RA (2005) Simultaneous analysis of thebaine, 6-MAM and six abused opiates in postmortem fluids and tissues using Zymark automated solid-phase extraction and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 822:137-145. (Pubitemid 40994045)
28. Lopez MF, Compton WM, and Volkow ND (2009) Changes in cigarette and illicit drug use among US teenagers. Arch Pediatr Adolesc Med 163:869-870.
29. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, and Kosten TR (2009) Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66:1116-1123.
30. Maxwell JC (2011) The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev 30:264-270.
31. Mayrose I, Shlomi T, Rubinstein ND, Gershoni JM, Ruppin E, Sharan R, and Pupko T (2007) Epitope mapping using combinatorial phage-display libraries: a graphbased algorithm. Nucleic Acids Res 35:69-78. (Pubitemid 46189832)
32. Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, et al. (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65:191-198. (Pubitemid 30018012)
33. Pöyhiä R, Olkkola KT, Seppälä T, and Kalso E (1991) The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol 32:516-518.
34. Pöyhiä R, Seppälä T, Olkkola KT, and Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617-621.
35. Pravetoni M, Keyler DE, Raleigh MD, Harris AC, Lesage MG, Mattson CK, Pettersson S, and Pentel PR (2011) Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol 81:1164-1170.
36. Sayre LM and Portoghese PS (1980) Stereospecific synthesis of the 6-α- and 6-β- amino derivatives of naltrexone and oxymorphone. J Org Chem 45:3366-3368. (Pubitemid 11242267)
37. Stotts AL, Dodrill CL, and Kosten TR (2009) Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 10:1727-1740.
38. Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, Mayorov AV, Zakhari JS, Koob GF, and Janda KD (2011) A vaccine strategy that induces protective immunity against heroin. J Med Chem 54:5195-5204.
39. Wainer BH, Fitch FW, Rothberg RM, and Fried J (1972) Morphine-3-succinyl- bovine serum albumin: an immunogenic hapten-protein conjugate. Science 176: 1143-1145.
40. Wainer BH, Fitch FW, Rothberg RM, and Schuster CR (1973) In vitro morphine antagonism by antibodies. Nature 241:537-538.